High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Luca BertaminiStefania OlivaDelia Rota-ScalabriniLaura ParisSonia MorèPaolo CorradiniAntonio LeddaMassimo GentileGiovanni De SabbataGiuseppe PietrantuonoAnna PascarellaPatrizia TosiPaola CurciMilena GilestroAndrea CapraPiero GalieniFrancesco PisaniOmbretta AnnibaliFederico MonacoAnna Marina LiberatiSalvatore PalmieriMario LuppiRenato ZambelloFrancesca FazioAngelo BelottiPaola TacchettiPellegrino MustoMario BoccadoroFrancesca GayPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In multiple myeloma, increasing levels of CTC above an optimal cutoff represent an easy-to-assess, robust, and independent high-risk factor. The achievement of MRD negativity is the most important factor that modulates their negative prognostic impact.